Document is current
Any future updates will be listed below
-
Authors
Mao, Nan
Xu, Zuoheng
Su, Jianfen
Wang, Bingna
Xia, Jiajing
Zheng, Diqun
Liao, Jianxing
Liu, Xiaoyan
-
Funding
Funding for this research was provided by:
the Research Funds from Guangzhou Panyu Central Hospital (PY-2023-007, PY-2023-010, PY-2023-026)
the Research Funds from Guangzhou Panyu Central Hospital (PY-2023-007, PY-2023-010, PY-2023-026)
the Research Funds from Guangzhou Panyu Central Hospital (PY-2023-007, PY-2023-010, PY-2023-026)
the Research Funds from Guangzhou Panyu Central Hospital (PY-2023-007, PY-2023-010, PY-2023-026)
Guangdong Basic and Applied Basic Research Fund Enterprise Joint Fund (2023A1515220024)
Medical Research Foundation of Guangdong Province (2024070)
Guangdong Hospital Pharmaceutical Research Fund project funding (2024A31)
- License Information
-
More Information
Article History
Received: 22 August 2024
Accepted: 2 December 2024
First Online: 16 December 2024
Declarations
:
: This clinical trial was registered in the China Drug Trials Registry ( ; registration number: CTR20210441; registration date: March 11, 2021). It was approved by the Ethics Committee of Panyu Central Hospital (Clinical Research Ethics Committee approval number: PYZXYYEC【2020–029】) and was conducted independently at the Phase I Clinical Trial Research Center of Panyu Central Hospital from March 15, 2021, to April 12, 2021. This study complied with the requirements of the Declaration of Helsinki (1989), Guidelines of Good Clinical Practice, and other related guiding principles.
: Informed consent was obtained from all individual participants included in the trial.
: There are no identifying details in this manuscript.
: The authors declare no competing interests.
